Article Text

Download PDFPDF
CASE REPORT
Macrophage activation syndrome/haemophagocytic lymphohistiocytosis secondary to Burkholderia cepacia complex septicaemia in an elderly female carrier of X-linked chronic granulomatous disease with extreme lyonisation: ‘cepacia syndrome’ revisited
  1. Nicolás Urriola1,
  2. Andrew Williams2 and
  3. Karuna Keat1
  1. 1 Immunology, Campbelltown Hospital, Campbelltown, New South Wales, Australia
  2. 2 Immunopathology, Children’s Hospital at Westmead, Westmead, New South Wales, Australia
  1. Correspondence to Dr Nicolás Urriola, nicolas.urriola{at}health.nsw.gov.au

Abstract

X-linked carriers of chronic granulomatous disease (CGD) may become phenotypically affected if substantial skewing from lyonisation occurs. We describe a 73-year-old female carrier with an overt CGD phenotype due to skewed lyonisation, complicated by macrophage activation syndrome (MAS)/haemophagocytic lymphohistiocytosis (HLH) secondary to Burkholderiacepacia complex septicaemia that was successfully treated with a combination of three antibiotics, an antifungal, granulocyte colony stimulating factor, intravenous immune globulin (IVIG) and ciclosporin. Fully phenotypic immunodeficiency is possible in X-linked CGD carriers when skewed lyonisation occurs, rendering such patients to all the same sequelae of CGD such as MAS/HLH. MAS/HLH should be thoroughly excluded when evaluating ‘cepacia syndrome’ in non-CGD patients.

  • immunology
  • pneumonia (respiratory medicine)
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors NU acted as the main author. KK provided editorial assistance and review. AW was responsible for CYBB gene sequencing validation and performance/interpretation of all neutrophil function testing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.